Law Firms Vie for aTyr Investor Lead as Dec. 8 Class Action Deadline Approaches
Investors have until December 8 to seek lead-plaintiff status over alleged misstatements tied to efzofitimod’s Phase 3 failure.
Overview
- Glancy Prongay & Murray, Rosen Law Firm, and The Gross Law Firm issued notices urging aTyr shareholders to move for lead-plaintiff status by December 8, 2025.
- Glancy and Gross define the class period as November 7, 2024 through September 12, 2025, while Rosen sets it as January 16, 2025 through September 12, 2025.
- The complaints allege aTyr misled investors about efzofitimod’s efficacy and the EFZO-FIT study design, including claims about enabling complete steroid tapering.
- aTyr disclosed on September 15, 2025 that EFZO-FIT failed its primary endpoint on steroid dose reduction at week 48, and the stock closed down 83.2% that day to $1.02.
- The suits are pending and no class has been certified, and notices emphasize that investors may choose counsel or remain absent class members as the company engages the FDA on next steps.